Literature DB >> 2574562

New acquisitions in the development of anti-HIV agents.

E De Clercq1.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2574562     DOI： 10.1016/0166-3542(89)90064-8

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  11 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives.

Authors:  M Baba; E De Clercq; S Iida; H Tanaka; I Nitta; M Ubasawa; H Takashima; K Sekiya; K Umezu; H Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 3.  Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry.

Authors:  V Nair; T S Jahnke
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

4.  An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.

Authors:  Z Debyser; R Pauwels; K Andries; J Desmyter; M Kukla; P A Janssen; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

5.  Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.

Authors:  M Baba; E De Clercq; H Tanaka; M Ubasawa; H Takashima; K Sekiya; I Nitta; K Umezu; H Nakashima; S Mori
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

6.  Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.

Authors:  M Baba; M Ito; S Shigeta; H Tanaka; T Miyasaka; M Ubasawa; K Umezu; R T Walker; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; A J Jowett; M I Jowett; B A Pearson; C R Penn; P L Rouse; K C Viner; J M Cameron
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Inhibition of visna virus replication by 2',3'-dideoxynucleosides and acyclic nucleoside phosphonate analogs.

Authors:  H Thormar; J Balzarini; A Holy; J Jindrich; I Rosenberg; Z Debyser; J Desmyter; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.

Authors:  Tetsuya Hosaka; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Masahiro Kobayashi; Takashi Someya; Hitomi Sezaki; Norio Akuta; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2007-05-25       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.